Oxycodone Hydrochloride Market Report 2026

Oxycodone Hydrochloride Market Overview

• Oxycodone Hydrochloride market size has reached to $4.32 billion in 2025 • Expected to grow to $5.18 billion in 2030 at a compound annual growth rate (CAGR) of 3.6% • Growth Driver: Surge In Chronic Pain Prevalence Fueling The Growth Of The Market Due To Rising Cases Of Long-Term Pain • Market Trend: New Generic Combination Products Provide Potent And Safer Pain Relief Options • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oxycodone Hydrochloride Market?

Oxycodone hydrochloride is a potent opioid analgesic used to relieve moderate to severe pain. It works by binding to opioid receptors in the brain and spinal cord to reduce the perception of pain. It is commonly prescribed for pain management after surgery, injury, or for chronic conditions. The main products of oxycodone hydrochloride are extended-release tablets, immediate-release tablets, oral solutions, and extended-release capsules. Extended-release tablets are medications designed to release their active ingredient gradually over time to maintain consistent drug levels and reduce dosing frequency. Oxycodone hydrochloride is administered through both oral and parenteral routes and is commonly used for pain management, including post-surgical pain and cancer-related pain. The product is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and it serves multiple end users, including hospitals, clinics, and home care settings.

What Is The Oxycodone Hydrochloride Market Growth Forecast?

The oxycodone hydrochloride market size is expected to see steady growth in the next few years. It will grow to $5.18 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to development of abuse-deterrent and tamper-resistant formulations, growing focus on controlled and regulated opioid use, expansion of generic drug manufacturing, rising cancer incidence and palliative care demand, innovation in pain management delivery systems. Major trends in the forecast period include rising demand for effective pain management therapies, growing use of extended release and abuse-deterrent formulations, increasing prescriptions for post-surgical and cancer-related pain, shift toward generic and cost-effective opioid formulations, strengthening regulatory oversight and controlled distribution.

What Is The Driver Of The Oxycodone Hydrochloride Market?

The increasing prevalence of chronic pain is expected to propel the growth of the oxycodone hydrochloride market going forward. Chronic pain, defined as pain persisting for three months or more, places a substantial burden on patients’ quality of life and creates growing demand for effective pain-management therapies. The rise in chronic pain cases is primarily attributed to factors such as obesity, aging populations, and musculoskeletal disorders, which increase the incidence of conditions like osteoarthritis and lower back pain. Oxycodone hydrochloride supports chronic pain management by targeting pain receptors in the nervous system, providing relief from moderate-to-severe pain, and improving patient comfort and daily functioning. For instance, in November 2024, according to the U.S. National Center for Health Statistics (NCHS), a US- based federal agency, 24.3% of U.S. adults experienced chronic pain, and 8.5% reported high-impact chronic pain, which limits life or work activities. Therefore, the increasing prevalence of chronic pain is driving the growth of the oxycodone hydrochloride industry.

Key Players In The Global Oxycodone Hydrochloride Market

Major companies operating in the oxycodone hydrochloride market are Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Purdue Pharma L.P., Alvogen Inc., Camber Pharmaceuticals, Noramco Inc., Rhodes Pharmaceuticals L.P., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Mylan N.V., Cipla Ltd., Torrent Pharmaceuticals Ltd., Sandoz International GmbH, Pfizer Inc., Novartis AG, Accord Healthcare Ltd., Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG

Global Oxycodone Hydrochloride Market Trends and Insights

Major companies operating in the oxycodone hydrochloride market are focusing on developing advanced products, such as combination therapies, to enhance pain management efficacy while reducing opioid dependency risks. Combination therapies refer to treatment approaches that use two or more medications or therapeutic agents together to enhance effectiveness, target multiple pathways, or reduce the risk of resistance. For instance, in April 2025, Elite Pharmaceuticals Inc., a US-based pharmaceutical company, launched a generic version of Percocet (oxycodone hydrochloride and acetaminophen tablets, USP CII). This combination product is available in three strengths mg/325 mg, 10 mg/325 mg, and 325 mg tablets. It is used for the relief of moderate to moderately severe pain, combining the opioid oxycodone for potent pain relief with acetaminophen to enhance analgesic effects. As a Schedule II controlled substance, it carries a high potential for abuse and dependence, requiring careful medical supervision.

What Are Latest Mergers And Acquisitions In The Oxycodone Hydrochloride Market?

In June 2024, Elite Pharmaceuticals Inc., a US-based pharmaceutical company, partnered with Nostrum Laboratories Inc. to acquire three approved abbreviated new drug applications (ANDAs) for generic versions of Norco, Percocet, and Dolophine. This partnership aims to expand their portfolio of generic opioid analgesics, enhance market presence in pain management therapies, and provide more affordable alternatives to branded pain medications for patients. Nostrum Laboratories Inc. is a US-based pharmaceutical company that manufactures a prescription medication that combines oxycodone hydrochloride and acetaminophen in an oral solution.

What Defines the Oxycodone Hydrochloride Market?

The oxycodone hydrochloride market consists of sales of oxycodone injectable formulations, oxycodone nasal sprays, oxycodone suppositories, and percocet. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oxycodone Hydrochloride Market Report 2026?

The oxycodone hydrochloride market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oxycodone hydrochloride industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.